意大利百胜Esaote
百胜是世界领先的医疗诊断系统生产厂商之一，以欧洲为基地的领先的超声设备制造商，国际公认的专用磁共振设备的领军者，百胜在健康信息技术方面也是主力军之一.

25年来,百胜稳步成长。2006年净销售超过2.6亿欧元，相当于全球范围销售的60%。百胜约有85%的销售出自竞争激烈的市场，如欧洲、美国和中国。

今天，百胜集团约有1200名雇员，39%的员工在海外工作。研发部门约有260名有资质的技术人员（相当于全部雇员人数的20%以上），并参与国际性研究中心和大学合作。

1980年代初，百胜开始起步。

1980年代初， 安萨尔多生物医疗公司成立
1988年 - Ote Biomedica公司与Esacontrol公司的一个部门合并，成立百胜生物医疗公司
1991年 - 收购位于美国印地安那波里斯的Biosound公司，开始国际化进程
1992年 - 百胜荷兰公司和法国公司成立
1994年 - 投资者和百胜管理层收购公司股份，实现私有化
1996年 - 米兰证交所上市
1997年 - 百胜（中国有）限公司成立
1998年 - 收购荷兰派尔集团
1998年 - 博莱科成为主要股东
2003年 - 博莱科发起兼并，认购100%的股份资本
2004年 - 在中国深圳成立合资企业深圳百胜医疗科技有限公司
2006年 - 以Banca Intesa为首的投资者和以百胜董事会主席Carlo Castellano教授为首的百胜集团管理层收购100% 百胜股份
2007年 - 收购法国康强医疗公司
2007年 - 创建百胜印度亚太诊断设备公司
2007年 - 百胜和EbitAet S.p.A.及Imaging S.p.A.合并

Esaote is one of the world’s leading producers of medical diagnostic systems. It is well established as a Europe-based leading ultrasound manufacturer, and internationally acknowledged to be the world leader in dedicated MRI. The Esaote Group is also one of the main players in the sector of Information Technology for healthcare.

In January 2006 a new Company - called Imaging S.p.A. - was created in order to purhcase 100% of Esaote S.p.A. and its subsidiaries. Imaging was created by financial investors (Intesa San Paolo, Equinox, Mps Venture, Banca Carige) and by the managers of the Esaote Group. During 2006 and 2007 Imaging S.p.A. was a shareholder of Esaote and had no operative functions.

In November 2009 Esaote is acquired by Tutti S.p.A., a consortium of investors led by Ares Life Sciences holding 40% of the share capital, and including Intesa Sanpaolo, Equinox Two SCA, MPS Venture 2, Carige and a group of Esaote management, holding a combined 60% stake.

During its life Esaote has undergone a steady growth, achieving net sales of about 310 million euro in 2009 with a strong contribution of international sales equal to about 60%. Almost 85% of Esaote’s consolidated sales are derived from highly competitive markets such as European countries, USA and China.

Today the Esaote Group has about 1350 employees, 40% of which work abroad. The R&D structures employ about 270 qualified technicians (equal to 20% of total staff) and enjoy the co-operation of international research centres and universities.

 Early 1980’s - Ansaldo Biomedicale founded
1988 - Ote Biomedica and a division of Esacontrol merge to create Esaote Biomedica
1991 - Internationalization begun with Biosound, Indianapolis, USA
1992 - Esaote Biomedica Deutschland and Esaote France created
1994 - Management Buy-out of Esaote, backed by leading investors and privatization
1996 - Listed on the Milan Stock Exchange
1997 - Esaote China set up
1998 - Pie Medical Group (Holland) acquired (today Esaote Europe)
1998 - Bracco becomes major stakeholder
2003 - Bracco launches a take-over bid and subscribes to 100% of the share capital
2004 - SEMT joint venture set up in Shenzhen (People’s Republic of China)
2006 - 100% of Esaote acquired by Imaging S.p.A. , a company set up by a group of investors, together with the management
2007 - Kontron Medical (France) acquired
2007 - Esaote Asia Pacific Diagnostic, (New Delhi,India) created
2007 - Esaote S.p.A and EbitAet S.p.A. merge with Imaging S.p.A. and Imaging S.p.A. changes its name to Esaote S.p.A.
2008 - Esaote S.p.A. purchases 79% of Anima Medica LtdA, a company based in San Paolo, Brasil. This company distributes Esaote products in Brasil with the trademark "Esaote Healthcare do Brasil".
2009 - Esaote is acquired by Tutti S.p.A. - 3rd Management Buy-Out